EXTON, Pa., April 27, 2011 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that Charles Rowland, vice president and chief financial officer of ViroPharma, will present at the Deutsche Bank 36th Annual Healthcare Conference at 10:40 A.M. ET on Tuesday, May 3, 2011. The conference is being held at the InterContinental Hotel in Boston, MA.
Vincent Milano, president and chief executive officer of ViroPharma, will present at the Bank of America/Merrill Lynch 2011 Healthcare Conference at 3:40 P.M. PT (6:40 P.M. ET) on Wednesday, May 11, 2011. The conference is being held at the Wynn Hotel in Las Vegas, NV.
William Roberts, vice president, corporate communications of ViroPharma will present at the ThinkEquity 2nd Annual Healthcare Conference at 11:30 A.M. ET on Wednesday, May 25, 2011. The conference is being held at the Princeton Club in New York City.
ViroPharma's presentations will be webcast live for investors through www.viropharma.com and available for a period of 14 days following the conferences.
About ViroPharma Incorporated
ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing innovative products for physician specialists to enable the support of patients with serious diseases for which there is an unmet medical need, and providing rewarding careers to employees. ViroPharma commercializes Cinryze™ (C1 esterase inhibitor [human]) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE). ViroPharma commercializes Vancocin®, approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains (for prescribing information on ViroPharma's commercial products, please download the package inserts at http://www.viropharma.com/Products.aspx). ViroPharma currently focuses its drug development activities in diseases including C1 esterase inhibitor deficiency and C. difficile.
ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's web site, www.viropharma.com. The company encourages investors to consult these sections for more information on ViroPharma and our business.
SOURCE ViroPharma Incorporated